| Project/Area Number |
26860571
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
MAEMURA Koji
IKEDA Satoshi
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 肺動脈性肺高血圧症 / マイクロRNA / エンドセリン / 脂肪由来幹細胞(ADRCs) / バイオマーカー / 細胞移植療法 / 脂肪由来幹細胞 / 肺動脈平滑筋細胞 / マイクロＲＲＮＡ / 肺動脈生肺高血圧症 / Endothelin |
|---|
| Outline of Final Research Achievements |
We reported that, Adipose-derived regenerative cell (ADRC) therapy inhibited the development of pulmonary arterial hypertension (PAH) by reversing the changes in Endothelin expression and inflammatory cytokines. These findings suggest that ADRC therapy may open a novel strategy for treating PAH.
Micro-RNA(miRNA) are detectable in serum and might be useful biomarkers of human diseases. However, the role of miRNA in connective tissue disease-pulmonary arterial hypertension (CTD-PAH) is not fully understood. Form the microarray analysis, 16 miRNAs increased in pulmonary circulation of patients with CTD-PAH. The expression miRNA-A which was one of the 16 miRNAs that was increased in the patients with CTD-PAH. MiRNA-A increased proliferation of PA smooth muscle cells (SMC) and protected against apoptosis. Our study identified miRNA as a novel biomarker of CTD-PAH. Interference with this pathway may offer novel approaches to treating CTD-PAH.
|
